Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE American: ELMD) is a medical device company that develops, manufactures, and sells airway clearance therapy products, including the SmartVest® Airway Clearance System, for patients with compromised pulmonary function. Company news often highlights its role as a leader in airway clearance technologies and its focus on High Frequency Chest Wall Oscillation (HFCWO) therapy, particularly in the homecare setting.
Newsflow for Electromed frequently centers on financial results, such as quarterly and annual earnings releases that detail net revenues, operating income, net income, and segment performance in direct homecare and non-homecare markets. These announcements often discuss trends in referrals and approvals, sales force expansion, and gross margin dynamics, as well as commentary from management on operational execution and efficiency initiatives.
Investors can also expect corporate and capital markets updates, including announcements about share repurchase authorizations approved by the board of directors and index-related milestones, such as Electromed’s addition to the Russell 2000® and Russell 3000® indexes. The company issues press releases when it schedules earnings conference calls and webcasts, providing dial-in details and replay information.
Another recurring category of news involves investor conference participation. Electromed regularly announces its presence at events hosted by organizations such as Noble Capital Markets, LD Micro, Canaccord Genuity, and Investor Summit, where management presents the company’s airway clearance business and growth strategy to institutional and other investors.
For readers tracking ELMD, this news page provides a centralized view of Electromed’s earnings announcements, capital allocation decisions, index inclusions, and investor outreach activities, offering context on how the company is executing its strategy in the airway clearance therapy market.
Electromed, Inc. (NYSE American: ELMD) announced that it received FDA 510(k) clearance for its SmartVest® Clearway® Airway Clearance System, targeting High Frequency Chest Wall Oscillation (HFCWO) therapy. This modernized device enhances patient experience and outcomes with features like an intuitive touchscreen and lightweight design. The system is crucial for patients with chronic lung conditions, helping to clear mucus and reduce respiratory infections. Limited market release in the U.S. is expected soon.
Electromed, a leader in airway clearance technologies, reported Q1 FY 2023 net revenue of $10.7 million, up 7% year-over-year. Homecare revenue was $9.6 million, a 4% increase. Operating income fell to $44,000 from $538,000 due to supply chain challenges and non-recurring expenses. Net income dropped to $81,000 or $0.01 per diluted share, compared to $439,000 or $0.05 in Q1 FY 2022. The company repurchased $145,000 in stock and had $6.0 million in cash as of September 30, 2022.
Electromed, Inc. (NYSE American: ELMD) announced its participation in two key investor conferences in November 2022. The first is the Sidoti & Company November Micro-Cap Virtual Conference on November 9-10, 2022, where Kathleen Skarvan and Michelle Wirtz will present. The second is the Three Part Advisors 14th Annual Southwest IDEAS Conference on November 16-17, 2022, featuring Skarvan, Wirtz, and new CFO Brad Nagel. Live webcasts and replays will be available online.
Electromed, Inc. (AMEX: ELMD) will release its financial results for the first quarter of fiscal 2023 on November 8, 2022, after market close. The company will also host a conference call at 5:00 p.m. ET the same day to discuss these results. Interested parties can join the call by dialing (844) 826-3033 for domestic access or (412) 317-5185 for international participants, using pin number 10172207. A live webcast will be available in the Investor Relations section of Electromed’s website, with a replay accessible after the event.
Electromed, Inc. has appointed Brad Nagel as its new Chief Financial Officer, effective November 14, 2022. Nagel brings over 15 years of financial leadership experience, particularly from his role at Medtronic, where he contributed to significant revenue growth. Electromed's President, Kathleen Skarvan, expressed confidence in Nagel's ability to drive growth and create value in the company. The outgoing Interim CFO, Michelle Wirtz, will continue as Corporate Controller, ensuring leadership continuity during this transition.
Electromed, Inc. (NYSE American: ELMD), a pioneer in airway clearance technologies, will participate in the Issuer Direct 2022 Windy City Roundup on October 12-13, 2022. CEO Kathleen Skarvan and Interim CFO Michelle Wirtz will present on October 12 from 11:30 to 11:55 a.m. CT. Management is also available for one-on-one investor meetings. The event showcases Electromed's innovative solutions, including the SmartVest® Airway Clearance System, designed for patients with compromised pulmonary function. For more details and to join the presentation, visit this link.
Electromed (NYSE American: ELMD) reported record annual revenues of $41.7 million for FY 2022, a 16.5% increase over the previous year, driven by strong home care revenue growth of 15.2%. In Q4 FY 2022, net revenue grew by 19% to $11.3 million, with $0.4 million net income consistent with Q4 FY 2021. The company expanded its sales force and increased strategic investments in marketing and clinical studies. However, net income decreased slightly from FY 2021. Cash reserves stood at $8.2 million, while the company continues to prioritize revenue growth and market expansion for fiscal 2023.
Electromed, Inc. (NYSE American: ELMD) will release its financial results for the fiscal 2022 fourth quarter and year, ending June 30, 2022, on August 23, 2022, after the market closes. A conference call will follow at 5:00 p.m. ET to discuss the results, where interested parties can join via phone or webcast. Electromed specializes in airway clearance technologies and is headquartered in New Prague, Minnesota. More details are available on their website.
Electromed, Inc. (NYSE American: ELMD) has appointed Andrew Summers as an independent director, effective July 25, 2022. This comes alongside a new cooperation agreement with Summers Value Partners, which holds approximately 6.1% of Electromed's stock. Summers will also serve as Vice Chair of the Finance and Strategy Committee. The board aims to leverage Summers' extensive healthcare investment experience to enhance corporate strategy and shareholder value.
Electromed, Inc. (NYSE American: ELMD) announced that Kathleen Skarvan, President and CEO, and Michelle Wirtz, Interim CFO, will participate in the Canaccord Genuity 42nd Annual Growth Conference from August 8-11, 2022. They will also be available for one-on-one investor meetings on August 10, 2022. Electromed specializes in airway clearance technologies, including the SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. The company is based in New Prague, Minnesota, and was founded in 1992.